Filing Flows › Usana Health Sciences (USNA) › Q1 2026 › vs Q1 2025
Usana Health Sciences (USNA) Q1 2026 vs Q1 2025 (year over year)
Usana Health Sciences's revenue rose $679K (+0.3%) from $250M in Q1 2025 to $250M in Q1 2026. Gross margin 76.2% against 79.0% (-2.7 pts).
Usana Health Sciences, Q1 2026: revenue $250M (+0.3% year over year), operating margin 5.5%, net earnings $7.5M, operating cash flow $9.8M. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Gross margin | 76.2% | 79.0% | -2.7 pts |
| Operating margin | 5.5% | 6.3% | -0.7 pts |
| Net margin | 3.0% | 3.8% | -0.8 pts |
| Free cash flow margin | 2.8% | 5.1% | -2.2 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $250M | $250M | $679K | +0.3% |
| Gross profit | $191M | $197M | −$6.3M | -3% |
| Cost of revenue | $59.4M | $52.4M | $7.0M | +13% |
| Other income, net | $1.6M | $1.1M | $523K | +49% |
| Operating profit | $13.9M | $15.7M | −$1.8M | -11% |
| Operating expenses | $177M | $181M | −$4.5M | -2% |
| Pre-tax earnings | $15.5M | $16.7M | −$1.3M | -8% |
| SG&A | $88.3M | $91.4M | −$3.2M | -3% |
| Other operating costs | $88.7M | $90.0M | −$1.3M | -1% |
| Loss borne by minority interests | $556K | $112K | $444K | +396% |
| Net earnings | $7.5M | $9.4M | −$1.9M | -20% |
| Income tax | $8.5M | $7.4M | $1.1M | +14% |
| Operating cash sources | $19.2M | $20.6M | −$1.4M | -7% |
| Depreciation & amortization | $8.3M | $8.3M | −$62K | -0.7% |
| Share-based compensation | $3.5M | $2.9M | $574K | +20% |
| Working capital & other | $9.5M | $5.1M | $4.3M | +85% |
| Operating cash flow | $9.8M | $15.5M | −$5.7M | -37% |
| Free cash flow (OCF − capex) | $7.1M | $12.7M | −$5.6M | -44% |
| Capital expenditures | $2.6M | $2.8M | −$158K | -6% |
Questions
How much did Usana Health Sciences's revenue grow year over year in Q1 2026?
Usana Health Sciences's revenue rose $679K (+0.3%) from $250M in Q1 2025 to $250M in Q1 2026. Gross margin 76.2% against 79.0% (-2.7 pts).